US 12,257,264 B2
Combination therapy for HIV with adenosine derivative and capsid inhibitors
Lianhong Xu, Durham, NC (US); and Zhi Hong, Durham, NC (US)
Assigned to Brii Biosciences, Inc., Durham, NC (US)
Filed by Brii Biosciences, Inc., Durham, NC (US)
Filed on Dec. 20, 2023, as Appl. No. 18/391,316.
Application 18/391,316 is a continuation of application No. 17/583,815, filed on Jan. 25, 2022, granted, now 11,890,297.
Claims priority of provisional application 63/141,445, filed on Jan. 25, 2021.
Prior Publication US 2024/0180949 A1, Jun. 6, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61K 45/06 (2006.01); A61P 31/18 (2006.01)
CPC A61K 31/7076 (2013.01) [A61K 45/06 (2013.01); A61P 31/18 (2018.01)] 9 Claims
 
1. A pharmaceutical tablet comprising:
(a) a compound of Formula 4-A:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and
(b) a pharmaceutically acceptable carrier.